A Phase 2 interventional study of Mesenchymal stem cell and Placebo in Osteoarthritis, sponsored by SCARM Institute, Tabriz, Iran. Withdrawn at 1 site in Iran, Islamic Republic of. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-03-18.
Sponsored by SCARM Institute, Tabriz, Iran · Phase 2, Interventional, and Treatment
Among 13 studies in Osteoarthritis with a site in Iran, Islamic Republic of — 1 open to participants now, 1 under way, none of them phase 3. Osteoarthritis · Iran, Islamic Republic of.
Among the 13 studies in Osteoarthritis with a site in Iran, Islamic Republic of, this one is the 13th largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 2, and was the 10th registered.
2,974 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.
Browse Osteoarthritis studies →1 of the 13 studies in Osteoarthritis with a site in Iran, Islamic Republic of is open now. Recruiting first, the newest first:
University of Sistan and Baluchestan · Sites in Iran, Islamic Republic of
Ages 45–65 · Men only
A study can be open while its sites in Iran, Islamic Republic of have not opened yet or have stopped. Only those recruiting at a site in Iran, Islamic Republic of →
Of the 286 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 5
First in 2004; this study’s year is marked. 2 started in 2019.
Median enrollment 40 across the 13 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 6 most frequent:
SCARM Institute, Tabriz, Iran is the lead sponsor of 7 studies on the registry; none are open to participants now.
SCARM Institute, Tabriz, Iran has 1 study filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Osteoarthritis with a site in Iran, Islamic Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Osteoarthritis of the knee is one of the most common causes of disability among elderly. As the disease progresses the cartilage become frustrated, surrounding bone react to become thicker and inflammation occurs in subchondral bone seen in T2-weighted MRI as increase in signal density. Patients are treated initially by pain management. In patients who don't response to first line treatment invasive treatment like total knee replacement is done. The investigators designed this clinical study with the aim of evaluating therapeutic effects of intra-articular injection of bone marrow Mesenchymal Stem Cells (MSC) and stromal Vascular Fraction (SVF) in patients with severe knee osteoarthritis
This is single center, randomized, triple blind phase II clinical study. Patients will be divided into two groups of case and control. All subjects will undergo bone marrow aspiration. Mesenchymal Stem Cells will be isolated from bone marrow and stromal Vascular Fraction fram lipoaspirate, cultured and transplanted back to the knee joint. Patients of case group will receive cell injection 1 and 4 months after bone marrow aspiration. Placebo will be administered in this group 6 months after the first injection. Patients of control group will receive placebo 1 and 4 months after bone marrow aspiration. They all receive cell injection 6 months after first placebo injection. Follow up visit will occur at 2 and 6 weeks, and 3 and 6 months after the first injection. Radiological exams will be performed before and 6 months after the first injection by MRI. Clinical quantitative assessment will measure joint function by the WOMAC index and pain by the visual analogue scale
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection
Biological: Mesenchymal stem cell
The patients who are in control group and underwent placebo injection
Biological: Placebo
intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
Patients with knee joint osteoarthritis who underwent intra articular placebo injection
physical function improvement
Evaluation the physical function improvement Measured by WOMAC osteoarthritis index after cell injection
Time frame: 2 weeks
Change in pain density
Evaluation the changing of pain density measured by Visual Analogue Scale after cell injection
Time frame: 2 weeks
Joint swelling
Evaluation the joint swelling by physical examination after intra articular cell injection
Time frame: 3 months
Joint erythema
Evaluation the joint erythema by physical examination after cell injection
Time frame: 3 months
Deterioration of joint function
Evaluation the deterioration of joint function by physical examination after intra articular cell injection
Time frame: 3 months
Allergic reactions
Evaluation the allergic reactions like skin rash,skin erythema, dyspnea by physical examination after cell injection
Time frame: 3 months
Plan to share: No
Start is estimated for Nov 2019; primary completion for Aug 2020, 9 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mesenchymal Stem Cell
SCARM Institute, Tabriz, Iran